In the previous two years, Blue Cross reported record operating losses of about $380 million and $400 million, while in 2025, Point32 marked its fifth year of multimillion dollar operating losses
Retatrutide Retatrutide is a new weight loss treatment, manufactured by Eli Lilly, to treat obesity and type 2 diabetes
Alm disso, alguns estudos esto avaliando a possibilidade de usar a retatrutida para diminuir o risco e o avano de alguns tipos de cncer, como o de pncreas e o de pulmo
Clinical trials may involve different patient populations, doses, treatment lengths, diabetes status, lifestyle support, and study designs
Rushing the injection creates a high-pressure bolus of medication that mechanically disrupts tissue and triggers a stronger inflammatory response
Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes